nach oben

Journal of General Internal Medicine

Erschienen in:

19.08.2020 | Clinical Vignette

Embolic Stroke Caused by Hereditary Hemorrhagic Telangiectasia with Pulmonary Arteriovenous Malformation

verfasst von: Keishiro Sueda, MD, Masao Horiuchi, MD, Hiraku Funakoshi, MD, MPH, PhD, Eiji Hiraoka, MD, PhD

Erschienen in: Journal of General Internal Medicine | Ausgabe 12/2020

Einloggen, um Zugang zu erhalten

Excerpt

Given that emboli are responsible for the majority of non-lacunar ischemic strokes, a standardized evaluation is recommended to determine major cardiac and arterial sources.¹ Major cardiac sources (e.g., atrial fibrillation and left ventricular thrombus) are identified by electrocardiogram (ECG) and transthoracic echocardiography. Imaging of the carotid and cerebral arteries, such as computed tomography (CT) and magnetic resonance imaging (MRI), can identify common atherothrombotic embolic sources. When embolic sources are not identified by the standard approach, non-lacunar strokes are deemed embolic stroke of undetermined sources (ESUS), which may merit from further evaluation.¹ …

Hart RG, Diener HC, Coutts SB, et al. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol. 2014;13:429-38.CrossRef

Cottin V, Dupuis-Girod S, Lesca G, Cordier J-F. Pulmonary vascular manifestations of hereditary hemorrhagic telangiectasia (Rendu-Osler disease). Respiration. 2007;74:361-78.CrossRef

Coley SC, Jackson JE. Pulmonary arteriovenous malformations. Clin Radiol. 1998;53:396-404.CrossRef

Pollak JS, Saluja S, Thabet A, Henderson KJ, Denbow N, White RI, Jr. Clinical and anatomic outcomes after embolotherapy of pulmonary arteriovenous malformations. J Vasc Interv Radiol. 2006;17:35-44.CrossRef

Montaner J, Perea-Gainza M, Delgado P, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke. 2008;39:2280-7.CrossRef

Shovlin CL, Guttmacher AE, Buscarini E, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet. 2000;91:66-7.CrossRef

Perera KS, Vanassche T, Bosch J, et al. Embolic strokes of undetermined source: Prevalence and patient features in the ESUS Global Registry. Int J Stroke. 2016;11:526-33.CrossRef

Ntaios G, Papavasileiou V, Milionis H, et al. Embolic strokes of undetermined source in the Athens stroke registry: a descriptive analysis. Stroke. 2015;46:176-81.CrossRef

Nouh A, Hussain M, Mehta T, Yaghi S. Embolic Strokes of Unknown Source and Cryptogenic Stroke: Implications in Clinical Practice. Front Neurol. 2016;7:37.CrossRef

10.

Abushora MY, Bhatia N, Alnabki Z, Shenoy M, Alshaher M, Stoddard MF. Intrapulmonary shunt is a potentially unrecognized cause of ischemic stroke and transient ischemic attack. J Am Soc Echocardiogr. 2013;26:683-90.CrossRef

11.

Dakeishi M, Shioya T, Wada Y, et al. Genetic epidemiology of hereditary hemorrhagic telangiectasia in a local community in the northern part of Japan. Hum Mutat. 2002;19:140-8.CrossRef

12.

Guttmacher AE, McKinnon WC, Upton MD. Hereditary hemorrhagic telangiectasia: a disorder in search of the genetics community. Am J Med Genet. 1994;52:252-3.CrossRef

13.

Donaldson JW, McKeever TM, Hall IP, Hubbard RB, Fogarty AW. The UK prevalence of hereditary haemorrhagic telangiectasia and its association with sex, socioeconomic status and region of residence: a population-based study. Thorax. 2014;69:161-7.CrossRef

14.

Shovlin CL, Jackson JE, Bamford KB, et al. Primary determinants of ischaemic stroke/brain abscess risks are independent of severity of pulmonary arteriovenous malformations in hereditary haemorrhagic telangiectasia. Thorax. 2008;63:259-66.CrossRef

15.

Silva BM, Hosman AE, Devlin HL, Shovlin CL. Lifestyle and dietary influences on nosebleed severity in hereditary hemorrhagic telangiectasia. Laryngoscope. 2013;123:1092-9.CrossRef

16.

Plauchu H, de Chadarevian JP, Bideau A, Robert JM. Age-related clinical profile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989;32:291-7.CrossRef

17.

Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet. 2009;17:860-71.CrossRef

18.

Livesey, JA, Manning, RA, Meek, JH et al. Low serum iron levels are associated with elevated plasma levels of coagulation factor VIII and pulmonary emboli/deep venous thromboses in replicate cohorts of patients with hereditary haemorrhagic telangiectasia. Thorax, 2012;67, 328-33.CrossRef

19.

Faughnan ME, Palda VA, Garcia-Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet. 2011;48:73-87.CrossRef

20.

Mager JJ, Overtoom TT, Blauw H, Lammers JWJ, Westermann CJ. Embolotherapy of Pulmonary Arteriovenous Malformations: Long-term Results in 112 Patients. J Vasc Interv Radiol. 2004;15:451-6.CrossRef

Titel: Embolic Stroke Caused by Hereditary Hemorrhagic Telangiectasia with Pulmonary Arteriovenous Malformation
verfasst von: Keishiro Sueda, MD
Masao Horiuchi, MD
Hiraku Funakoshi, MD, MPH, PhD
Eiji Hiraoka, MD, PhD
Publikationsdatum: 19.08.2020
Verlag: Springer International Publishing
Erschienen in: Journal of General Internal Medicine / Ausgabe 12/2020
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI: https://doi.org/10.1007/s11606-020-06126-0

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypertonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Embolic Stroke Caused by Hereditary Hemorrhagic Telangiectasia with Pulmonary Arteriovenous Malformation

Excerpt

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2020

Comparing Associations of State Reopening Strategies with COVID-19 Burden

Peer Review at JGIM

Challenges with Accuracy of Gender Fields in Identifying Transgender Patients in Electronic Health Records

Peer Support for Self-Management of Chronic Pain: the Evaluation of a Peer Coach-Led Intervention to Improve Pain Symptoms (ECLIPSE) Trial

Identifying Patients with Persistent Preventable Utilization Offers an Opportunity to Reduce Unnecessary Spending

Minding the Gap: Organizational Strategies to Promote Gender Equity in Academic Medicine During the COVID-19 Pandemic

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Metformin rückt in den Hintergrund

Update Innere Medizin